Research ArticleArticle
Open Access
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Penélope Esther Palominos, Daniel G. Fernández-Ávila, Laura C. Coates, Adewale Adebajo, Adrien Nzeusseu Toukap, Ahmed Abogamal, Ari Polachek, Arno W.R. van Kuijk, Francesco Caso, Gabriele de Marco, Gurjit S. Kaeley, Ingrid Steinkoenig, Jeffrey Chau, Marie Feletar, Marijn Vis, Ori Elkayam, Philipp Sewerin, Salvatore d'Angelo, Sibel Zehra Aydin, Waleed AlShehhi and Philip S. Helliwell
The Journal of Rheumatology November 2022, jrheum.220311; DOI: https://doi.org/10.3899/jrheum.220311
Penélope Esther Palominos
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Daniel G. Fernández-Ávila
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Laura C. Coates
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Adewale Adebajo
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Adrien Nzeusseu Toukap
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Ahmed Abogamal
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Ari Polachek
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Arno W.R. van Kuijk
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Francesco Caso
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Gabriele de Marco
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Gurjit S. Kaeley
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Ingrid Steinkoenig
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Jeffrey Chau
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Marie Feletar
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Marijn Vis
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Ori Elkayam
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Philipp Sewerin
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Salvatore d'Angelo
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Sibel Zehra Aydin
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Waleed AlShehhi
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Philip S. Helliwell
This work was supported by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a registered nonprofit organization. GRAPPA receives funding from pharmaceutical companies, presently AbbVie, Amgen, Boehringer Ingelheim, BMS, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, with Galapagos and Nordic Bioscience as Innovation Partners. All deliberations and decisions concerning this literature review and data interpretation were made completely independently of, and without input from or review by, any industry representatives. P.E. Palominos, MD, PhD, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; D.G. Fernández-Ávila, MD, PhD, Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia; L.C. Coates, MD, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK; A. Nzeusseu Toukap, MD, Rheumatology Department, Saint-Luc University Hospitals, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; A. Abogamal, MD, PhD, Al-Azhar Faculty of Medicine, Cairo, Egypt; A. Polachek, MD, Department of Rheumatology, Sourasky Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; A.W.R. van Kuijk, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands; F. Caso, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; G. de Marco, MD, Leeds Biomedical Research Center at Leeds Teaching Hospitals NHS Trust, and University of Leeds, Leeds, UK; G.S. Kaeley, MD, University of Florida College of Medicine, Jacksonville, Florida, USA; I. Steinkoenig, BA, GRAPPA Patient Research Partner, Cleveland, Ohio, USA; J. Chau, MCS, GRAPPA Patient Research Partner, Hong Kong SAR, China; M. Feletar, MD, Dandenong Rheumatology, Melbourne, Australia; M. Vis, MD, PhD, Department of Rheumatology, Erasmus MC, Rotterdam, the Netherlands; O. Elkayam, MD, Department of Rheumatology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; P. Sewerin, MD, PhD, Heinrich-Heine-Universität Duesseldorf, University Hospital Duesseldorf, Department and Hiller Research-Unit for Rheumatology, Duesseldorf, Germany; S. d'Angelo, MD, PhD, Rheumatology Institute of Lucania, and Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; S.Z. Aydin, MD, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; W. AlShehhi, MD, Dr. Suliman Alhabib Hospital, Dubai, UAE; P.S. Helliwell, MD, PhD, Leeds University, Leeds, UK. PEP received honoraria/research grants from AbbVie, Janssen, Novartis, Pfizer, and UCB. A. Abogamal received honoraria as a speaker and advisor for Janssen, Pfizer, Lilly, Novartis, AbbVie, and Amgen. ANT received honoraria/grants from AbbVie, Novartis, UCB, Lilly, Celgene, Amgen, MSD, Janssen, and Pfizer. MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer. SdA has received consulting and speaking fees outside the submitted work from AbbVie, Amgen, BMS, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB. SZA has received honoraria/research grants from AbbVie, Celgene, UCB, Novartis, Janssen, Pfizer, Eli Lilly, and Sanofi. PSH has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. P.E. Palominos, Rheumatology Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecilia, Porto Alegre - RS, 90035-903, Brazil. Email: penelopepalominos@gmail.com. Accepted for publication July 6, 2022.
Abstract
Objective This literature review aimed to identify the most efficacious current interventions for dactylitis and provide up-to-date scientific evidence to support the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations on the management of psoriatic arthritis.
Methods Original articles published from 2013 to 2020, registered in MEDLINE, Embase, and Cochrane Library, describing interventional trials and reporting dactylitis-related outcomes were included. The 20 members of the GRAPPA dactylitis group were divided into 9 subgroups according to treatment, and members of each group independently extracted data from articles/abstracts corresponding to their group by using a standardized data extraction form.
Results Forty-nine publications were analyzed, representing 40 randomized clinical trials (RCTs) and including 16,752 patients. Dactylitis was assessed as a secondary outcome in 97.5% of these trials and more than 40% of RCTs did not employ a specific dactylitis measure or instrument.
Conclusion The emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis. This article points out the lack of consensus regarding dactylitis assessment and the paucity of data concerning the effect of local steroid injections, nonsteroidal antiinflammatory drugs, and conventional disease-modifying antirheumatic drugs. Clinical trials evaluating the effect of these traditional and low-cost medications used to treat dactylitis should be encouraged.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Penélope Esther Palominos, Daniel G. Fernández-Ávila, Laura C. Coates, Adewale Adebajo, Adrien Nzeusseu Toukap, Ahmed Abogamal, Ari Polachek, Arno W.R. van Kuijk, Francesco Caso, Gabriele de Marco, Gurjit S. Kaeley, Ingrid Steinkoenig, Jeffrey Chau, Marie Feletar, Marijn Vis, Ori Elkayam, Philipp Sewerin, Salvatore d'Angelo, Sibel Zehra Aydin, Waleed AlShehhi, Philip S. Helliwell
The Journal of Rheumatology Nov 2022, jrheum.220311; DOI: 10.3899/jrheum.220311
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Penélope Esther Palominos, Daniel G. Fernández-Ávila, Laura C. Coates, Adewale Adebajo, Adrien Nzeusseu Toukap, Ahmed Abogamal, Ari Polachek, Arno W.R. van Kuijk, Francesco Caso, Gabriele de Marco, Gurjit S. Kaeley, Ingrid Steinkoenig, Jeffrey Chau, Marie Feletar, Marijn Vis, Ori Elkayam, Philipp Sewerin, Salvatore d'Angelo, Sibel Zehra Aydin, Waleed AlShehhi, Philip S. Helliwell
The Journal of Rheumatology Nov 2022, jrheum.220311; DOI: 10.3899/jrheum.220311
